Integral Derivatives’s Elevance Health ELV Stock Holding History

Integral Derivatives’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,620	Closed	-$2.02M	–	764
2017 Q4	$1.94M	Buy	8,620 +3,826	+80%	+$815K	0.04%	303
2017 Q3	$910K	Buy	+4,794	New	+$912K	0.02%	521
2015 Q4	–	Sell	-1,991	Closed	-$279K	–	1104
2015 Q3	$279K	Buy	+1,991	New	+$299K	0.01%	879

Other funds holding ELV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Integral Derivatives's ELV Position: Q1 2018 in Review

Integral Derivatives sold out of Elevance Health (ELV) in Q1 2018, closing a stake of 8,620 shares — an estimated $2.02M sold.

Integral Derivatives first reported a position in ELV in Q3 2015 and held it in 3 quarters. The position peaked at $1.94M in Q4 2017. 923 funds tracked by Wall St. Rank hold ELV as of Q1 2018.

Integral Derivatives reported no remaining Elevance Health position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 8,620 Elevance Health shares in Q1 2018, an estimated $2.02M.
Integral Derivatives first reported a position in Elevance Health in Q3 2015 and held it in 3 quarters.
Integral Derivatives's Elevance Health position peaked at $1.94M in Q4 2017.
923 funds tracked by Wall St. Rank held Elevance Health as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.